We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $71.46, moving +2.26% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. Elsewhere, the Dow saw an upswing of 0.91%, while the tech-heavy Nasdaq depreciated by 0.82%.
Shares of the pharmaceutical have depreciated by 2.85% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 29, 2025. The company's earnings per share (EPS) are projected to be $1.11, reflecting a 12.12% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.03 billion, indicating a 8.42% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.49 per share and a revenue of $57.68 billion, signifying shifts of +9.25% and +6.67%, respectively, from the last year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 15.55 right now. This denotes a discount relative to the industry average Forward P/E of 18.72.
Also, we should mention that AZN has a PEG ratio of 1.28. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.34 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
Astrazeneca (AZN - Free Report) closed the most recent trading day at $71.46, moving +2.26% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. Elsewhere, the Dow saw an upswing of 0.91%, while the tech-heavy Nasdaq depreciated by 0.82%.
Shares of the pharmaceutical have depreciated by 2.85% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 29, 2025. The company's earnings per share (EPS) are projected to be $1.11, reflecting a 12.12% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.03 billion, indicating a 8.42% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.49 per share and a revenue of $57.68 billion, signifying shifts of +9.25% and +6.67%, respectively, from the last year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 15.55 right now. This denotes a discount relative to the industry average Forward P/E of 18.72.
Also, we should mention that AZN has a PEG ratio of 1.28. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.34 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.